(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Significant Elements to Consider Prior to Applying for a Mastercard: 6 Vital Contemplations - 2'The Drama' plot twist, explained: What did Zendaya's character do, and what happens to her wedding?
- 3Favored Vehicle for Seniors: Make Your Determination
- 4Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- 5Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- Conquering Social Generalizations: Individual Accounts of Strengthening
- How to see the Ursids, the final meteor shower of 2025
- Pick Your Favored method of transportation
- Map shows more than 1,900 measles cases across U.S.
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- Vote in favor of your #1 Kind of Cap
- ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- Misjudged Objections For Solo Voyagers
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
